Cartalax: Benefits, Dosage and Side Effects in 2026
Cartalax is the AED tripeptide, a cartilage bioregulator from the St Petersburg short-peptide program12. Clinics describe it for cartilage and joint support and recovery after joint injury345. No human trial has been published, no clinic publishes a dose, and it is not FDA-approved5.
Also called Kartalax and the AED peptide. Part of the bioregulator family; compare BPC-157.
Last updated November 17, 2026 by the Prof. Peptide editorial team
What is Cartalax?
Cartalax is a synthetic tripeptide, alanine, glutamic acid and aspartic acid (AED), from the St Petersburg Institute of Bioregulation and Gerontology, where its studies were done12. Clinics describe it as a tissue-specific peptide for cartilage health and joint repair4. It is not FDA-approved, and research-grade Cartalax is not a prescription product5.
Where to buy Cartalax?
Cartalax is not FDA-approved. Research-grade Cartalax is sold by specialty peptide vendors for laboratory use only, with no label behind it. The vendors listed here sell it, each with Prof. Peptide's code. Each vendor name links to its Prof. Peptide page, with the vendor's catalog, testing and shipping details.
True Peptide Labs: Buy 2, get 1 free with Prof. Peptide’s flash-sale code, ends Nov 17 · checked Nov 12. All current deals
Mizan Supply: 40% off every vial through November 30, and Prof. Peptide’s code takes 10% more, ends Nov 30 · checked Nov 11. All current deals
How much does Cartalax cost?
Cartalax costs from $1.08 to $5.58 per mg after Prof. Peptide's code, across 30 listings from 30 vendors, with prices as of November 16, 2026; the median listing is $2.44 per mg. Listings are shown lowest first. The price on top is after the PROFPEPTIDE discount code, and the crossed-out price is the vendor's regular price.
Prices as of November 16, 2026; a listing read earlier shows its own date
Price trend, vendors' own listed price before any code (median per mg): $3.32 on August 18, 2026 → $3.00 on November 16, 2026. These medians come from the nightly price file, which held 17 listings on the first date and 34 listings on the last, including listings the table above leaves out (vendors excluded, retired or not re-read recently); more vendors were added over the period.
What are Cartalax's uses and reported benefits?
Cartalax is prescribed by clinics for cartilage and joint support, joint comfort and stiffness, and recovery after joint injury345. What they describe is their own practice, not evidence: the human record is one line in a 2023 review, which states it was given orally to older patients with osteoarthritis without reporting a trial or numbers2.
| Use area | Clinical reports | Human studies |
|---|---|---|
| Cartilage and joint support | Clinics describe it to support cartilage health, joint repair and protection against degenerative change, in clinician-guided protocols for mobility and cartilage support34. | A 2023 review states it was given orally to older patients with osteoarthritis; no trial, numbers or regimen are reported2. |
| Joint comfort and stiffness | Clinics list joint comfort, cartilage symptoms and reduced stiffness among what it is researched for5. | No published trial for this use. |
| Recovery after joint injury | Clinics describe it for post-traumatic joint injury, sports-related cartilage stress and overuse syndromes, and recovery34. | No published trial for this use. |
How does Cartalax work?
Cartalax's proposed mechanism, as clinics explain it, is on the cells that make cartilage: it is said to raise the activity of genes for cartilage matrix, collagen and proteoglycan, to lower genes linked to degeneration and inflammation, and to reduce matrix metalloproteinase activity4. The studies behind that account are summarized further down this page16.
- Clinics also say what it is not: not a painkiller, not a steroid, and not a replacement for joint alignment or physical therapy4.
How is Cartalax dosed?
No trial has set a Cartalax dose, and no clinic was found publishing one after searching 13 clinic sources, the eight largest US peptide clinics among them345. One clinic lists it on prescription as a 25 mg vial at a patient price of $120, ordered only after a clinician review and a free consultation3.
Clinic practice
No trial or label sets a dose for Cartalax. Clinic listings are credited by name; they are not trial results and not advice.
Need to calculate a dose?
Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.
Open CalculatorHow is Cartalax taken?
What are the side effects of Cartalax?
Cartalax's side effects have not been reported by any trial, and no adverse-event data exist. Clinics describe it as well tolerated, non-hormonal and not suppressing immune function, and say it does not stimulate abnormal tissue growth4; those are the clinic's statements, not measured results.
What clinics report
Is Cartalax legal?
Cartalax is not FDA-approved for any use; clinics describe it as research only5, one lists it for prescription after a clinician review3, and research-grade vials are sold for laboratory use only. In sport, the 2026 WADA Prohibited List does not name it, and its S0 class prohibits unapproved substances at all times.
Legal status
- FDA: FDA's Category 2 list of bulk substances that may present significant compounding safety risks, current as of April 22, 2026, does not name Cartalax or the AED peptide7.
- Sport: not named on the 2026 WADA Prohibited List, whose S0 class prohibits at all times any substance with no current approval for human therapeutic use.
- Research-grade vials: sold for laboratory use only, not for human use; a research-use label does not make a vial an approved or prescribed product.
What do human studies show about Cartalax?
No human trial of Cartalax has been published. The only human-use statement is in a 2023 review from the institute that developed it, which says the AED tripeptide has shown high efficacy with oral administration in older patients with osteoarthritis2; the abstract gives no trial, numbers or regimen, and the reports behind it were not located.
What does animal and lab research show about Cartalax?
Cartalax's lab evidence is two cell-culture studies from one institute. In aged chondrocytes, the AED peptide normalized markers of an aging-associated secretory phenotype, p16, p21, p53, TNF-α, IL-1α and Sirt11; in aging human mesenchymal stem cells, 200 ng/mL raised SOX9, aggrecan, type II collagen and COMP6. A 2023 review also cites animal models of osteoarthritis2.
Cartalax FAQ
What is Cartalax?
Cartalax is the AED tripeptide (alanine, glutamic acid and aspartic acid), the cartilage-directed member of the St Petersburg short-peptide bioregulator family12. Clinics describe it as a peptide to support cartilage health and joint repair4. It is not FDA-approved and has no published human trial. See What is Cartalax?
Is there a standard Cartalax dose?
Cartalax has no standard dose: no trial has set one, and no clinic was found publishing one after searching 13 clinic sources. One clinic lists it on prescription as a 25 mg vial, ordered after a clinician review3. The 2023 review mentions oral use without a regimen2. See How is Cartalax dosed?
Is Cartalax FDA-approved?
No. Cartalax is not FDA-approved for any use; clinics describe it as research only5, one lists it for prescription after a clinician review3, and research-grade vials are sold for laboratory use only. In sport, the 2026 WADA Prohibited List does not name it, and its S0 class prohibits unapproved substances at all times. See Is Cartalax legal?
Where can I buy Cartalax?
Cartalax is not FDA-approved, so no approved product exists. Research-grade material is sold by peptide vendors for laboratory use only. Where to buy Cartalax? lists vendors with Prof. Peptide's code, and How much does Cartalax cost? compares prices. The verified discount codes page lists every vendor with a code.
References
- Peptides prevent the forming of secretory phenotype of chondrocytes associated with the agingAnimal and labMyakisheva SN, Linkova NS, Kozhevnikova EO, et al. Adv Gerontol. 2023 (in Russian). Abstract read November 6, 2026.Key finding: Chondrocyte culture: AED and a cartilage polypeptide complex normalized p16, p21, p53, TNF-α, IL-1α and Sirt1.PubMed 37356100 →
- Chondrocytes secretory phenotype associated with aging: role in the pathogenesis of osteoarthritis and prospects for peptide bioregulationReviewMyakisheva SN, Linkova NS, Kozhevnikova EO, Ryzhak GA. Adv Gerontol. 2023 (in Russian). Abstract read November 6, 2026.Key finding: States that the AED tripeptide (Kartalax) showed high efficacy in animal models of osteoarthritis and with oral administration in older patients.PubMed 37782637 →
- Shop: Cartalax (25mg)TelehealthMy Flow MD. Page read November 5, 2026.myflowmd.com →
- Cartalax peptide explained: cartilage repair, joint health, and anti-inflammatory supportClinicRevolution Health & Wellness, Sapulpa, Oklahoma; January 16, 2026. Page read November 5, 2026.revolutionhealth.org →
- Cartalax: research and statusClinicTrue Heal Wellness, New Jersey. Page read November 5, 2026.truehealwellness.com →
- The influence of peptides on the chondrogenic differentiation of human mesenchymal stem cells during replicative agingAnimal and labMyakisheva SN, Linkova NS, Diatlova AS, et al. Adv Gerontol. 2023 (in Russian). Abstract read November 6, 2026.Key finding: AED at 200 ng/mL raised SOX9, aggrecan, type II collagen and COMP in aging mesenchymal stem cells.PubMed 37782646 →
- Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2)RegulatorU.S. Food and Drug Administration. Content current as of April 22, 2026; read November 6, 2026.fda.gov →
Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.
Have a question about Cartalax? Send us an email
Checked and updated



